Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines-Selecting Compounds for Clinical Evaluation in Coronavirus Disease 2019 Clinical Trials.

"Dr. Buchman’s institution received funding from the United States Government; he disclosed that his institution receives a stipend for his work as Editor in Chief of Critical Care Medicine. Drs. Buchman, Adam, Aggarwal, Fessel, Higgs, Menetski, and Read disclosed government work. Dr. Draghia-Akli disclosed she is an employee of J&J; she disclosed that one of the J&J assets has been independently selected for inclusion in Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines (ACTIV)-1, which is funded by the National Institutes of Health (NIH). Dr. Aggarwal disclosed support from ACTIV public-private partnership. Drs. Adam, Higgs, and Menetski received support for article research from the NIH. Dr. Hughes received funding from Novartis Pharmaceuticals."

"Dr. Buchman’s institution received funding from the United States Government; he disclosed that his institution receives a stipend for his work as Editor in Chief of Critical Care Medicine. Drs. Buchman, Adam, Aggarwal, Fessel, Higgs, Menetski, and Read disclosed government work. Dr. Draghia-Akli disclosed she is an employee of J&J; she disclosed that one of the J&J assets has been independently selected for inclusion in Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines (ACTIV)-1, which is funded by the National Institutes of Health (NIH). Dr. Aggarwal disclosed support from ACTIV public-private partnership. Drs. Adam, Higgs, and Menetski received support for article research from the NIH. Dr. Hughes received funding from Novartis Pharmaceuticals."